Kitaura Atsuhiro, Yoshino Yukari, Sakamoto Hiroatsu, Sakuma Risa, Hirano Urara, Yuasa Haruyuki, Nakajima Yasufumi
Anesthesiology, Kindai University Faculty of Medicine, Osaka, JPN.
Anesthesiology, Nagoya University, Nagoya, JPN.
Cureus. 2025 Jul 23;17(7):e88622. doi: 10.7759/cureus.88622. eCollection 2025 Jul.
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune-mediated complication of heparin therapy, often resulting in thrombotic events despite adequate anticoagulation. Rapid-onset HIT is a particularly severe variant that occurs within 24 hours of re-exposure to heparin in sensitized individuals with circulating anti-platelet factor 4 (PF4)/heparin antibodies. Although rare, its potential for rapid progression and fatal outcomes necessitates a high index of clinical suspicion, especially in perioperative settings involving routine heparin use. We report the case of an 84-year-old female who underwent transcatheter aortic valve replacement (TAVR) following a prior percutaneous coronary intervention (PCI) with unfractionated heparin exposure two weeks earlier. There was no significant decrease in platelet count before or after the PCI, with values remaining stable from 240,000 to 220,000/μL. Shortly after intraoperative heparin administration during TAVR, the patient developed sudden hemodynamic collapse. Transesophageal echocardiography revealed a transient intracardiac thrombus-like echogenic mass approximately 10 minutes after administration of unfractionated heparin, followed 20 minutes later by acute left ventricular wall motion abnormalities and cardiogenic shock. Emergent venoarterial extracorporeal membrane oxygenation (VA-ECMO) and urgent percutaneous coronary intervention were performed after coronary angiography revealed occlusion of the left anterior descending artery. Subsequently, the TAVR procedure was completed. Surgical complications and ectopic deep vein thrombosis were excluded. The intraoperative 4Ts score ranged from 3 to 4, making the suspicion of HIT equivocal. Although we hesitated to initiate argatroban therapy under these circumstances, heparin was discontinued. Fortunately, the activated clotting time (ACT) remained prolonged. The patient was weaned from VA-ECMO and transferred to the intensive care unit (ICU). Delayed emergence from sedation was noted following ICU admission. A contrast-enhanced computed tomography scan obtained three hours after the conclusion of surgery demonstrated systemic embolization, including infarctions in the right middle cerebral artery and the kidney. The cerebral infarction was deemed ineligible for reperfusion therapy, and a best supportive care approach was adopted. The patient died on postoperative day 10. Based on the patient's clinical course, a final 4Ts score of 6, and a positive immunoassay for HIT antibodies (PF4/heparin enzyme-linked immunosorbent assay (ELISA)), the patient was clinically diagnosed with rapid-onset HIT on postoperative day 4, despite the absence of confirmatory testing using functional assays. Although intraoperative findings suggestive of HIT were observed, distinguishing these from other TAVR-related complications proved clinically challenging, leading to a delayed diagnosis. This case report underscores the importance of recognizing the risk of HIT in patients with a history of heparin exposure and highlights critical areas for improvement in perioperative management strategies.
肝素诱导的血小板减少症(HIT)是肝素治疗罕见但严重的免疫介导并发症,即便进行了充分抗凝,仍常导致血栓形成事件。快速发作型HIT是一种特别严重的变体,在已致敏且循环中有抗血小板因子4(PF4)/肝素抗体的个体再次接触肝素后24小时内发生。尽管罕见,但其快速进展和致命后果的可能性要求临床高度怀疑,尤其是在涉及常规使用肝素的围手术期。我们报告一例84岁女性病例,该患者两周前曾接受普通肝素抗凝的经皮冠状动脉介入治疗(PCI),之后接受经导管主动脉瓣置换术(TAVR)。PCI前后血小板计数无显著下降,数值在240,000至220,000/μL之间保持稳定。TAVR术中给予肝素后不久,患者突然发生血流动力学崩溃。经食管超声心动图显示,给予普通肝素后约10分钟出现一过性心内血栓样回声团块,20分钟后出现急性左心室壁运动异常和心源性休克。冠状动脉造影显示左前降支闭塞后,紧急进行了静脉 - 动脉体外膜肺氧合(VA - ECMO)和紧急经皮冠状动脉介入治疗。随后,TAVR手术完成。排除了手术并发症和异位深静脉血栓形成。术中4Ts评分在3至4分之间,使得HIT的怀疑不明确。尽管在这种情况下我们对启动阿加曲班治疗犹豫不决,但停用了肝素。幸运的是,活化凝血时间(ACT)仍延长。患者撤离VA - ECMO并转入重症监护病房(ICU)。入住ICU后发现镇静后苏醒延迟。手术后三小时进行的对比增强计算机断层扫描显示全身栓塞,包括右大脑中动脉和肾脏梗死。脑梗死被认为不适合进行再灌注治疗,因此采取了最佳支持治疗方法。患者于术后第10天死亡。根据患者的临床病程、最终4Ts评分为6分以及HIT抗体免疫测定(PF4/肝素酶联免疫吸附测定(ELISA))呈阳性,尽管未使用功能测定进行确诊检测,但患者在术后第4天临床诊断为快速发作型HIT。尽管观察到术中表现提示HIT,但在临床上难以将其与其他TAVR相关并发症区分开来,导致诊断延迟。本病例报告强调了认识肝素暴露史患者中HIT风险的重要性,并突出了围手术期管理策略中关键的改进领域。